Skip to main content
Terug
KSPHF logo

Kissei Pharmaceutical Co., Ltd.

Datakwaliteit: 100%
Oversold
KSPHF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 25,77
€ 0,00 (0,00%)
Marktkapitalisatie: 1,07B
Dagbereik
€ 25,77 € 30,28
52-Weeksbereik
€ 23,23 € 31,90
Volume
100
50D / 200D Gem.
€ 26,83 / € 27,79
Vorige Slotkoers
€ 25,77

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,3
P/B 0,0 2,9
ROE % 5,6 3,7
Net Margin % 13,5 3,8
Rev Growth 5Y % 6,4 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 318,00
€ 291,47 – € 335,78
 110 B 1
FY2029 € 309,94
€ 284,08 – € 327,27
 110 B 1
FY2028 € 339,24
€ 310,94 – € 358,21
 100 B 1

Belangrijkste Punten

Revenue grew 6,35% annually over 5 years — modest growth
Debt/Equity of 0,01 — conservative balance sheet
Generating 1,49B in free cash flow
P/E of 0,09 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10,52%
Capital efficient — spends only 5,69% of revenue on capex

Groei

Revenue Growth (5Y)
6,35%
Revenue (1Y)16,87%
Earnings (1Y)7,18%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
5,58%
ROIC2,06%
Net Margin13,54%
Op. Margin6,54%

Veiligheid

Debt / Equity
0,01
Current Ratio6,45
Interest Coverage274,90

Waardering

P/E Ratio
0,09
P/B Ratio0,01
EV/EBITDA-3,95
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16,87% Revenue Growth (3Y) 14,40%
Earnings Growth (1Y) 7,18% Earnings Growth (3Y) 6,59%
Revenue Growth (5Y) 6,35% Earnings Growth (5Y) 22,65%
Profitability
Revenue (TTM) 88,33B Net Income (TTM) 11,96B
ROE 5,58% ROA 4,90%
Gross Margin 49,89% Operating Margin 6,54%
Net Margin 13,54% Free Cash Flow (TTM) 1,49B
ROIC 2,06% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 6,45
Interest Coverage 274,90 Dividend Yield 0,02%
Valuation
P/E Ratio 0,09 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 1,16
EV/EBITDA -3,95 Dividend Yield 0,02%
Market Cap 1,07B Enterprise Value -22,82B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 88,33B 75,58B 67,49B 65,38B 69,04B
Net Income 11,96B 11,16B 10,53B 12,92B 5,29B
EPS (Diluted) 274,21 246,58 228,31 280,20 113,25
Gross Profit 44,07B 37,34B 223,56M 238,41M 279,53M
Operating Income 5,77B 4,02B -1,13B -1,40B 1,51B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 244,06B 260,93B 1,66B 1,96B 2,43B
Total Liabilities 33,93B 39,80B 198,58M 297,46M 442,57M
Shareholders' Equity 209,00B 220,03B 193,90B 201,38B 219,31B
Total Debt 1,28B 1,34B 1,49B 1,64B 1,74B
Cash & Equivalents 25,17B 22,89B 367,95M 246,56M 393,19M
Current Assets 106,98B 104,55B 100,64B 99,34B 92,97B
Current Liabilities 16,58B 17,66B 14,96B 18,74B 18,25B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#783 of 827
12
Growth Price/Sales Ratio Focus (Ken Fisher)
#463 of 618
19
Value Defensive Investing (Benjamin Graham)
#666 of 709
3

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026